While mature data from trials have demonstrated that periodic rounds of low-dose CT scan reduce lung-cancer related mortality, major issues are now implementation of screening on a large-scale and how to engage the target population
Trastuzumab has transformed the prognosis for women with HER2+ breast cancer. On the occasion of the ESMO Breast Cancer Virtual Congress 2021, leading oncology experts recall with enthusiasm the pioneering work of researchers like José Baselga in this field and push for continuous research to investigate how to further improve the treatment of this cancer sub-type
Could the daunting biology of small-cell lung cancer provide the key to elucidating drug resistance?
At ELCC 2021, Prof. Fiona Blackhall sees hope for improving patients’ poor prognoses on the horizon
With multiple new therapies available, Prof. Johan Vansteenkiste says the search is on for biomarkers to better match patients to treatments
With the growing use of real-world evidence (RWE) to support regulatory approvals of new anti-cancer medicines in Europe and the USA, can this type of research ensure greater inclusion of women, the elderly, diverse ethnic groups, those with rare cancers and other under-represented populations in oncology studies?
Real-world research does not need to replace randomised clinical trials to be recognised as valuable for treatment evaluation
According to Prof. Urania Dafni, high quality real-world evidence can provide broader information and more generalisable conclusions to verify the clinical applicability of evidence from RCTs
During the COVID-19 pandemic, real-world data have shown they can support clinical decision-making in complex situations but extensive bureaucracy is still a limiting factor
Promising results with cancer vaccines based on specific antigen mutations in individual tumours, and typically used in combination with checkpoint inhibitors, are fuelling an upsurge of interest in cancer vaccination for patients with established cancer, explains Prof. Pedro Romero.